- Companies
- Cyclezyme
Cyclezyme Valuation Multiples
Cyclezyme is valued at $8M as of October 2026, a 94.3x revenue multiple. In the last fiscal year, Cyclezyme revenue was $84K and Cyclezyme EBITDA was ($148K).
Cyclezyme Overview
About Cyclezyme
Cyclezyme AB is a Sweden-based company that has developed an enzymatic platform focused on producing enzymes for green biochemical processes. This platform utilizes biotechnological methods to identify and improve enzymes capable of converting e.g. PET-based plastic materials for new building blocks. The company enables careful experiments and analyses of the behavior of different enzymes in the breakdown of e.g. PET material. The company refines its enzymes and also optimizes the processes for plastic recycling by combining experimental data with data analysis.
Founded
N/A
HQ
Employees
N/A
Website
Sectors
Financials (Last FY)
EV
$8M
Valuation Multiples
Start free trialCyclezyme Financials
Cyclezyme reported last fiscal year revenue of $84K and negative EBITDA of ($148K).
In the same fiscal year, Cyclezyme generated $249K in gross profit, ($148K) in EBITDA losses, and had net loss of ($157K).
Cyclezyme P&L
In the most recent fiscal year, Cyclezyme reported revenue of $84K and EBITDA of ($148K).
Cyclezyme is unprofitable as of last fiscal year, with gross margin of 297%, EBITDA margin of (177%), and net margin of (188%).
Financial data powered by Morningstar, Inc.
Cyclezyme Stock Performance
Cyclezyme has current market cap of $8M, and enterprise value of $8M.
Market Cap Evolution
Cyclezyme's stock price is $2.81.
Cyclezyme share price increased by 1.0% in the last 30 days, and by 52.5% in the last year.
Cyclezyme has an EPS (earnings per share) of $-0.06.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $8M | $8M | 4.8% | 1.0% | -5.4% | 52.5% | $-0.06 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialCyclezyme Valuation Multiples
Cyclezyme trades at 94.3x EV/Revenue multiple, and (53.2x) EV/EBITDA.
Cyclezyme Financial Valuation Multiples
As of October 4, 2026, Cyclezyme has market cap of $8M and EV of $8M.
Cyclezyme has a P/E ratio of (50.3x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Cyclezyme Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Cyclezyme Margins & Growth Rates
In the most recent fiscal year, Cyclezyme reported gross margin of 297%, EBITDA margin of (177%), and net margin of (188%).
Cyclezyme Margins
Cyclezyme Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Cyclezyme Operational KPIs
Data powered by FactSet, Inc. and Morningstar, Inc.
Cyclezyme Competitors
Cyclezyme competitors include Tribox Group, Berger Paints Jamaica, Suntrade Group, Sansuy Industria, Encres Dubuit, XP Chemistries, OrganoClick, Australian Silica Quartz, Prymus and Polygiene Group.
Most Cyclezyme public comparables operate across Chemicals.
| Last FY | EV/Revenue | EV/EBITDA | ||||||
|---|---|---|---|---|---|---|---|---|
| Revenue | EBITDA | Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| $12M | $633K | 0.7x | - | 13.4x | - | |||
| $21M | $898K | 0.3x | - | 7.2x | - | |||
| $614K | ($172K) | 12.2x | - | (43.4x) | - | |||
| $187M | ($681K) | 0.3x | - | (82.4x) | - | |||
| $20M | ($3M) | 0.2x | - | (1.0x) | - | |||
| $33K | ($901K) | 140.6x | 47.3x | (5.1x) | (4.2x) | |||
| $11M | ($1M) | 1.3x | - | (10.3x) | - | |||
| - | - | - | - | - | - | |||
This data is available for Pro users. Sign up to see all Cyclezyme competitors and their valuation data. Start Free Trial | ||||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Cyclezyme
| Where is Cyclezyme headquartered? | Cyclezyme is headquartered in Sweden. |
| Is Cyclezyme publicly listed? | Yes, Cyclezyme is a public company listed on Spotlight Stock Market. |
| What is the stock symbol of Cyclezyme? | Cyclezyme trades under CYCLE ticker. |
| When did Cyclezyme go public? | Cyclezyme went public in 2023. |
| Who are competitors of Cyclezyme? | Cyclezyme main competitors include Tribox Group, Berger Paints Jamaica, Suntrade Group, Sansuy Industria, Encres Dubuit, XP Chemistries, OrganoClick, Australian Silica Quartz, Prymus, Polygiene Group. |
| What is the current market cap of Cyclezyme? | Cyclezyme's current market cap is $8M. |
| What is the current revenue of Cyclezyme? | Cyclezyme's last fiscal year revenue is $84K. |
| What is the current EV/Revenue multiple of Cyclezyme? | Current revenue multiple of Cyclezyme is 94.3x. |
| Is Cyclezyme profitable? | No, Cyclezyme is not profitable. |
| How many companies Cyclezyme has acquired to date? | Cyclezyme hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Cyclezyme has invested to date? | Cyclezyme hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Cyclezyme
Lists including Cyclezyme
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.




